Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

John Burke, MD, regarding tafasitamab or tafasitamab + lenalidomide in addition to R-CHOP in DLBCL

Dr. Burke, Physician, Associate Chair, US Oncology Hematology Research Program, Medical Oncology/ Hematology, Rocky Mountain Cancer Centers, tells us about the design and objectives of the Phase Ib study assessing safety and preliminary efficacy of tafasitamab or tafasitamab plus lenalidomide in addition to R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL)

Tags: ASH Conference CoverageLymphoma (includes NHL, HL, CNS Lymphoma)

Published: 12 December 2019

Recent Videos

video

Case Study: Platinum Sensitive Recurrent High-Grade Serous Ovarian Cancer

Dr. Slomovitz, Professor of Obstetrics and Gynecology, Florida International University, Gynecologic Oncologist, Broward Health, and Dr. Kamath, Gynecologic Oncology Fellow, ...

video

Leslie Popplewell, MD, provides perspective on the ELARA study investigating the use of Kymriah (tisagenlecleucel) in follicular lymphoma patients that have received at least 2 prior therapies

Dr. Popplewell, Clinical Associate Professor, City of Hope, provides perspective on the ELARA study presented at ASCO20 and EHA20 investigating ...

video

Leslie Popplewell, MD, provides thoughts on the unique MOA of the newly FDA approved tazemetostat

Dr. Popplewell, Clinical Associate Professor, City of Hope, provides thoughts on the unique MOA of the newly FDA approved tazemetostat ...

video

Leslie Popplewell, MD, provides thoughts on the role Yescarta (axicabtagene ciloleucel) will play in low grade NHL management

Dr. Popplewell, Clinical Associate Professor, City of Hope, provides thoughts, based on the evidence presented at ASCO20, on the role ...

video

Leslie Popplewell, MD, on impressions of the Alexander trial investigating AUTO3(CAR-T cell therapy) as DLBCL treatment

Dr. Popplewell, Clinical Associate Professor, City of Hope, shares impressions of the Alexander trial investigating AUTO3 (CAR-T cell therapy) as ...

video

Leslie Popplewell, MD, discusses the potential practice changing outcomes of the Keynote-204 study presented at ASCO20

Dr. Popplewell, Clinical Associate Professor, City of Hope, discusses potential practice changing outcomes of the Keynote-204 study presented at ASCO20 ...

video

Andrew Zelenetz, MD, describes the study presented at ASCO 20 exploring the CIBMTR analysis of PET scans

Dr. Zelenetz, Medical Director, Memorial Sloan Kettering Cancer Center, describes the clinical study presented at ASCO20 exploring the CIBMTR analysis ...

video

Andrew Zelenetz, MD, discusses the validity and availability of the EZH2 companion diagnostic test

Dr. Zelenetz, Medical Director, Memorial Sloan Kettering Cancer Center, discusses the validity and availability of the EZH2 companion diagnostic test ...

video

Andrew Zelenetz, MD, provides thoughts on the unique MOA of the newly FDA approved tazemetostat

Dr. Zelenetz, Medical Director, Memorial Sloan Kettering Cancer Center, provides thoughts on the unique MOA of the newly FDA approved ...

video

Andrew Zelenetz, MD, provides the clinical progress and outcomes to date with the BOVen trial in CLL

Dr. Zelenetz, Medical Director, Memorial Sloan Kettering Cancer Center, provides the clinical progress and outcomes to date with the BOVen ...

Related Videos

video-image

Case Study: Platinum Sensitive Recurrent High-Grade Serous Ovarian Cancer

video-image

Leslie Popplewell, MD, discusses the potential practice changing outcomes of the Keynote-204 study presented at ASCO20

video-image

Leslie Popplewell, MD, on impressions of the Alexander trial investigating AUTO3(CAR-T cell therapy) as DLBCL treatment

video-image

Leslie Popplewell, MD, provides thoughts on the role Yescarta (axicabtagene ciloleucel) will play in low grade NHL management

video-image

Leslie Popplewell, MD, provides thoughts on the unique MOA of the newly FDA approved tazemetostat

video-image

Leslie Popplewell, MD, provides perspective on the ELARA study investigating the use of Kymriah (tisagenlecleucel) in follicular lymphoma patients that have received at least 2 prior therapies

video-image

Andrew Zelenetz, MD, provides thoughts on the potential practice changing outcomes of the Keynote-204 study

video-image

Andrew Zelenetz, MD, shares impressions of the Alexander trial investigating AUTO3 as treatment for DLBCL

video-image

Andrew Zelenetz, MD, examines whether Yescarta (axicabtagene ciloleucel) will play a significant role in low grade NHL management

video-image

Andrew Zelenetz, MD, shares some of the unique aspects in the clinical design of the BOVen study

video-image

Andrew Zelenetz, MD, provides the clinical progress and outcomes to date with the BOVen trial in CLL

video-image

Andrew Zelenetz, MD, provides thoughts on the unique MOA of the newly FDA approved tazemetostat

video-image

Andrew Zelenetz, MD, discusses the validity and availability of the EZH2 companion diagnostic test

video-image

Andrew Zelenetz, MD, describes the study presented at ASCO 20 exploring the CIBMTR analysis of PET scans

video-image

Rana McKay, MD, discusses the unmet needs for clinical trials addressing non-clear cell RCC

video-image

Rana McKay, MD, discusses factors considered when deciding which patients to get an I-O combo in RCC

video-image

Rana McKay, MD, shares results of the randomized Phase 2 study investigating luPSMA vs cabazitaxel

video-image

Rana McKay, MD, shares the design and outcomes of the Javelin Bladder 100 study

video-image

Rana McKay, MD, discusses the design and outcomes of the Phase 3 randomized Keynote 426 study in 1st line clear cell renal cell cancer (RCC)

video-image

Rana McKay MD, explains approach to treating 2nd-line RCC patients who have received I-O combination